"development of therapeutic medical countermeasures for biodefense and emerging infectious diseases" 09/16/13- 09/15/2015, $3,624,974
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN272201300018C
- Awardee
-
Trius Therapeutics, Inc. UEI MCPHH5DJ3GR6 Part of Cubist Pharmaceuticals, Inc.
- Awarding agency
-
NIAID DEA OA Acquisitions
National Institutes of Health, Department of Health and Human Services
- Obligated
- $845,876
Award facts
- Opportunity
-
- Development of Therapeutic Medical Countermeasures for Biodefense and Emerging Infectious Diseases Award Notice · Posted Sep 20, 2013
- Contract value 100% obligated
- $845,876.06 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 28 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- San Diego, CA 92121, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$1,925,153 | |
| Other Administrative Action | -$853,945 | |
| Rerepresentation of Non-Novated Merger/Acquisition | $0 | |
| Original award | $3,624,974 |
About this award
This is a $3,624,974 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services, to Trius Therapeutics, Inc. for the "DEVELOPMENT OF THERAPEUTIC MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES". The contract has a period of performance from September 16, 2013 to September 15, 2015, with a ceiling value of $845,876.06. There is no set-aside for this award. Trius Therapeutics, Inc. is a subsidiary of Cubist Pharmaceuticals, Inc. The contract is focused on the development of medical countermeasures for biodefense and emerging infectious diseases, which aligns with NIAID's mission to conduct research to understand, treat, and prevent infectious, immunologic, and allergic diseases.
Quick answers
Who was awarded contract HHSN272201300018C?
HHSN272201300018C was awarded to Trius Therapeutics, Inc. by NIAID DEA OA Acquisitions (National Institutes of Health) on September 12, 2013.
How much is contract HHSN272201300018C worth?
The government has obligated $845,876 on HHSN272201300018C.
Was contract HHSN272201300018C competed?
The extent of competition for HHSN272201300018C was full and open competition. The government received 28 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award